Nothing Special   »   [go: up one dir, main page]

PL2041177T3 - Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 - Google Patents

Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6

Info

Publication number
PL2041177T3
PL2041177T3 PL07777380T PL07777380T PL2041177T3 PL 2041177 T3 PL2041177 T3 PL 2041177T3 PL 07777380 T PL07777380 T PL 07777380T PL 07777380 T PL07777380 T PL 07777380T PL 2041177 T3 PL2041177 T3 PL 2041177T3
Authority
PL
Poland
Prior art keywords
receptor
human
high affinity
affinity antibodies
cdr2
Prior art date
Application number
PL07777380T
Other languages
English (en)
Inventor
Sean Stevens
Tammy T Huang
Joel H Martin
Jeanette L Fairhurst
Ashique Rafique
Eric Smith
Kevin J Pobursky
Nicholas J Papadopoulos
James P Fandl
Gang Chen
Margaret Karow
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38792460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2041177(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PL2041177T3 publication Critical patent/PL2041177T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL07777380T 2006-06-02 2007-06-01 Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 PL2041177T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81066406P 2006-06-02 2006-06-02
US84323206P 2006-09-08 2006-09-08
EP07777380A EP2041177B1 (en) 2006-06-02 2007-06-01 High affinity antibodies to human il-6 receptor
PCT/US2007/013062 WO2007143168A2 (en) 2006-06-02 2007-06-01 High affinity antibodies to human il-6 receptor

Publications (1)

Publication Number Publication Date
PL2041177T3 true PL2041177T3 (pl) 2012-09-28

Family

ID=38792460

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07777380T PL2041177T3 (pl) 2006-06-02 2007-06-01 Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
PL11171039T PL2374818T3 (pl) 2006-06-02 2007-06-01 Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11171039T PL2374818T3 (pl) 2006-06-02 2007-06-01 Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6

Country Status (33)

Country Link
US (9) US7582298B2 (pl)
EP (2) EP2374818B1 (pl)
JP (3) JP5307708B2 (pl)
KR (1) KR101464502B1 (pl)
CN (2) CN102585002A (pl)
AT (1) ATE537190T1 (pl)
AU (1) AU2007254831B2 (pl)
BR (1) BRPI0712224B8 (pl)
CA (1) CA2652976C (pl)
CR (1) CR10462A (pl)
CY (3) CY1112456T1 (pl)
DK (2) DK2041177T3 (pl)
ES (2) ES2398076T3 (pl)
GT (1) GT200800272A (pl)
HR (2) HRP20120175T1 (pl)
HU (1) HUS1700050I1 (pl)
IL (1) IL195393A (pl)
LT (1) LTC2041177I2 (pl)
LU (1) LUC00050I2 (pl)
ME (1) ME00519B (pl)
MX (1) MX2008014804A (pl)
MY (2) MY159787A (pl)
NL (1) NL300911I2 (pl)
NO (2) NO340778B1 (pl)
NZ (2) NZ573557A (pl)
PL (2) PL2041177T3 (pl)
PT (2) PT2041177E (pl)
RS (2) RS52176B (pl)
RU (1) RU2433138C2 (pl)
SI (2) SI2041177T1 (pl)
SV (1) SV2008003113A (pl)
TN (1) TNSN08502A1 (pl)
WO (1) WO2007143168A2 (pl)

Families Citing this family (358)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CN101537180B (zh) 2002-07-18 2016-02-10 莫鲁斯有限公司 抗体混合物的重组生产
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
EP4001409A1 (en) * 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
SI2041177T1 (sl) 2006-06-02 2012-03-30 Regeneron Pharma Visoko afinitetna protitelesa za humani IL receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
US8629244B2 (en) * 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2670583A1 (en) * 2006-11-30 2008-06-05 Medimmune, Llc Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US9725514B2 (en) 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
CN101868477A (zh) * 2007-05-21 2010-10-20 奥尔德生物制药公司 新型兔抗体人源化方法和人源化的兔抗体
HUE032563T2 (en) 2007-05-21 2017-09-28 Alderbio Holdings Llc Antibodies to IL-6 and their use
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
SI2187964T1 (sl) 2007-08-10 2015-01-30 Regeneron Pharmaceuticals, Inc. Visokoafinitetna humana protitelesa proti humanemu živčnemu rastnemu faktorju
WO2009041643A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Cdrのアミノ酸置換により抗体の等電点を改変する方法
EP2206775B1 (en) 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
CN101874041B (zh) 2007-09-26 2013-06-19 中外制药株式会社 抗体恒定区修饰体
SG10201608379YA (en) 2008-04-11 2016-11-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CN102089326B (zh) 2008-05-13 2014-12-31 诺维莫尼公司 抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法
CA2725169A1 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
US10717781B2 (en) 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
EP3456192A1 (en) 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
AU2012200724B8 (en) * 2008-09-26 2014-09-11 Chugai Seiyaku Kabushiki Kaisha Improved antibody molecules
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8062866B2 (en) * 2008-11-13 2011-11-22 Femta Pharmaceuticals, Inc. Humanized anti-IL-6 antibodies
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN105116138A (zh) * 2009-02-24 2015-12-02 艾斯巴技术-诺华有限责任公司 用于鉴定细胞表面抗原的免疫结合剂的方法
EP3181583A1 (en) * 2009-02-24 2017-06-21 ESBATech, an Alcon Biomedical Research Unit LLC Methods for identifying immunobinders of antigens
AU2010225951B2 (en) * 2009-03-19 2014-03-13 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
CN102388069B (zh) 2009-04-10 2016-01-20 埃博灵克斯股份有限公司 用于治疗il-6r相关疾病和病症的改进的针对il-6r的氨基酸序列和包含其的多肽
EP2417162A2 (en) * 2009-04-10 2012-02-15 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
NZ597481A (en) 2009-07-08 2013-10-25 Kymab Ltd Animal models and therapeutic molecules
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
KR101985153B1 (ko) * 2009-10-26 2019-05-31 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
WO2011066378A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat thrombosis
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
PT2509409T (pt) 2009-12-10 2016-09-29 Regeneron Pharma Ratinhos que produzem anticorpos de cadeia pesada
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
EP2501817B2 (en) 2010-02-08 2021-04-21 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
JP6033218B2 (ja) * 2010-05-21 2016-11-30 ペプティメド， インコーポレイテッド がんを治療するための試薬および方法
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
EP4115906A1 (en) 2010-05-28 2023-01-11 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
WO2011159938A2 (en) 2010-06-16 2011-12-22 Trellis Bioscience, Inc. High affinity human antibodies to human cytomegalovirus (cmv) gb protein
MX345251B (es) 2010-08-02 2017-01-23 Regeneron Pharma Ratones que producen proteinas de union que comprenden dominios vl.
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
US9533039B2 (en) 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
WO2012071561A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
WO2012073992A1 (ja) 2010-11-30 2012-06-07 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
US20120189621A1 (en) 2011-01-21 2012-07-26 Yann Dean Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists
KR20200133826A (ko) 2011-01-28 2020-11-30 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 특정 대상자 그룹의 치료 방법에 이용하기 위한 ｐｃｓｋ9에 대한 인간 항체
SI4067496T1 (sl) 2011-02-25 2023-07-31 Regeneron Pharmaceuticals, Inc. Miši ADAM6
CA2827581A1 (en) * 2011-03-03 2012-09-07 Apexigen, Inc. Anti-il-6 receptor antibodies and methods of use
AU2012239382B2 (en) * 2011-04-01 2016-04-21 Chugai Seiyaku Kabushiki Kaisha Recombinant polypeptide production method
PT2631654E (pt) 2011-05-12 2015-08-21 Regeneron Pharma Ensaio de libertação de neuropéptidos para canais de sódio
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
LT3865581T (lt) 2011-08-05 2024-10-25 Regeneron Pharmaceuticals, Inc. Pelės su humanizuota universalia lengvąja grandine
CN107056936B (zh) 2011-09-19 2021-09-03 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
EA201791393A3 (ru) 2011-09-30 2018-03-30 Ридженерон Фармасьютикалз, Инк. Антитела к erbb3 и их применение
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
SG10201914052TA (en) * 2011-10-11 2020-03-30 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same
KR20140082824A (ko) 2011-10-17 2014-07-02 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
WO2013059548A1 (en) 2011-10-19 2013-04-25 Sanofi Compositions and methods for treating cancer using jak2 inhibitor
CN103059137A (zh) * 2011-10-21 2013-04-24 神州细胞工程有限公司 抗hIL6R高亲和力抗体的制备及应用
WO2013059426A1 (en) * 2011-10-21 2013-04-25 The Regents Of The University Of California Human endogenous retrovirus peptides, antibodies to the peptides, and methods of use thereof
SG11201400945UA (en) 2011-10-28 2014-04-28 Regeneron Pharma Humanized il-6 and il-6 receptor
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
BR112014012460B1 (pt) 2011-11-23 2021-01-12 Bioven 3 Limited proteínas recombinantes
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
CA2859408C (en) 2011-12-20 2020-06-16 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
LT3453723T (lt) * 2012-01-31 2021-09-10 Regeneron Pharmaceuticals, Inc. Antikūnai prieš asic1 ir jų panaudojimas
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
UY34652A (es) 2012-03-02 2013-09-02 Regeneron Pharma Anticuerpos humanos frente a toxinas de clostridium difficile
CN107090471A (zh) 2012-03-06 2017-08-25 瑞泽恩制药公司 共同轻链小鼠
CA2865643A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
RU2014141536A (ru) 2012-03-16 2016-05-10 Регенерон Фармасьютикалз, Инк. Мыши, которые продуцируют антигенсвязывающие белки с зависимыми от величины ph характеристиками связывания
SMT201900535T1 (it) 2012-03-16 2019-11-13 Regeneron Pharma Roditori esprimenti sequenze di immunoglobulina sensibile al ph
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
EA035344B1 (ru) 2012-04-20 2020-05-29 Мерюс Н.В. Способ получения двух антител из одной клетки-хозяина
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
RU2656155C2 (ru) 2012-06-12 2018-05-31 Регенерон Фармасьютикалз, Инк. Гуманизированные не относящиеся к человеку животные с ограниченными локусами тяжелой цепи иммуноглобулина
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
EP4324479A3 (en) 2012-08-21 2024-04-24 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
EP3354663A1 (en) 2012-09-07 2018-08-01 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
AU2013345018A1 (en) 2012-11-13 2015-05-14 Regeneron Pharmaceuticals, Inc. Anti-prokineticin receptor (PROKR) antibodies and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
ES2678221T3 (es) 2013-02-20 2018-08-09 Regeneron Pharmaceuticals, Inc. Animales no humanos con secuencias de cadena pesada de inmunoglobulina modificadas
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
ES2712207T3 (es) 2013-03-13 2019-05-09 Regeneron Pharma Ratones que expresan un repertorio limitado de cadenas ligeras de inmunoglobulina
JP2016519568A (ja) 2013-03-13 2016-07-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 共通軽鎖のマウス
EP2970481A2 (en) 2013-03-14 2016-01-20 Regeneron Pharmaceuticals, Inc. Human antibodies to nav1.7
CA2904644C (en) 2013-03-14 2022-09-20 Regeneron Pharmaceuticals, Inc. Human antibodies to grem1
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
JP6463351B2 (ja) 2013-06-21 2019-01-30 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
EP3036543B1 (en) 2013-08-23 2019-06-19 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
CA2922892C (en) 2013-09-18 2022-06-14 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
SG10201802295XA (en) 2013-10-01 2018-04-27 Kymab Ltd Animal Models and Therapeutic Molecules
EP3063543B1 (en) 2013-10-31 2020-03-11 Regeneron Pharmaceuticals, Inc. Competitive ligand binding assay for detecting neutralizing antibodies
CA2931299C (en) 2013-11-20 2024-03-05 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015095511A2 (en) * 2013-12-20 2015-06-25 The Scripps Research Institute Functional antibodies that modulate cell death and related methods
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
WO2015116852A1 (en) * 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CN106459199B (zh) 2014-03-11 2021-01-01 瑞泽恩制药公司 抗-egfrviii抗体及其用途
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
WO2016044337A1 (en) 2014-09-16 2016-03-24 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof
US9840557B2 (en) 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof
CA2963712A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
CA2967602A1 (en) 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
MX2017006312A (es) 2014-11-17 2017-08-21 Regeneron Pharma Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
JP2017536391A (ja) * 2014-12-02 2017-12-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−６ｒアンタゴニストを投与することによってドライアイ疾患を治療するための方法
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
KR101892883B1 (ko) 2015-02-27 2018-10-05 추가이 세이야쿠 가부시키가이샤 Il-6 관련 질환 치료용 조성물
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
MX2017013267A (es) 2015-04-15 2018-08-15 Regeneron Pharma Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8).
JP2016208934A (ja) * 2015-05-12 2016-12-15 学校法人日本大学 抗イヌインターロイキン−６受容体モノクローナル抗体又は抗体フラグメント及びその利用
PL3299810T3 (pl) 2015-05-19 2021-12-13 National Center Of Neurology And Psychiatry Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm)
WO2016195088A1 (ja) 2015-06-04 2016-12-08 国立研究開発法人 国立精神・神経医療研究センター Ｉｌ－６阻害剤を有効成分とする精神疾患治療剤
KR20180025865A (ko) 2015-07-06 2018-03-09 리제너론 파마슈티칼스 인코포레이티드 다중특이적 항원 결합 분자 및 이의 용도
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
MX2018002000A (es) 2015-08-18 2018-06-19 Regeneron Pharma Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
SI3394103T1 (sl) 2015-12-22 2023-10-30 Regeneron Pharmaceuticals, Inc. Kombinacija protiteles proti-PD-1 in bispecifičnih protiteles proti-CD20/proti-CD3 za zdravljenje raka
CA3004288A1 (en) 2015-12-28 2017-07-06 Nobuyuki Tanaka Method for promoting efficiency of purification of fc region-containing polypeptide
EP4257599A3 (en) 2016-01-13 2024-01-17 Regeneron Pharmaceuticals, Inc. Rodents having an engineered heavy chain diversity region
JP2019509059A (ja) 2016-02-16 2019-04-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 変異型キヌレニナーゼ遺伝子を有する非ヒト動物
EP3216461A1 (en) 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
KR20180114955A (ko) 2016-03-07 2018-10-19 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 류마티스 관절염의 치료를 위한 조성물 및 방법
AU2017248356A1 (en) 2016-04-08 2018-10-25 Regeneron Pharmaceuticals, Inc. Methods for treating hyperlipidemia with an ANGPTL8 inhibitor and an ANGPTL3 inhibitor
KR20230098361A (ko) 2016-04-20 2023-07-03 리제너론 파마슈티칼스 인코포레이티드 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
IL262268B2 (en) * 2016-04-20 2024-05-01 Regeneron Pharma Compositions and methods for making antibodies based on use of an expression-enhancing locus
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
TWI822521B (zh) 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
CN109475109B (zh) 2016-05-20 2021-10-29 瑞泽恩制药公司 用于使用多个引导rna来破坏免疫耐受性的方法
WO2017201731A1 (en) * 2016-05-27 2017-11-30 Beijing Vdjbio Co., Ltd. Antibodies, composition and kits comprising same, and methods of use thereof
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
CN109563170B (zh) 2016-06-10 2023-10-13 瑞泽恩制药公司 抗gitr抗体及其用途
PT3468990T (pt) 2016-06-14 2024-06-25 Regeneron Pharma Anticorpos anti-c5 e utilizações dos mesmos
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
RU2656160C2 (ru) * 2016-08-17 2018-05-31 Закрытое Акционерное Общество "Биокад" Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
MX2019002344A (es) 2016-09-01 2019-09-06 Regeneron Pharma Metodos de prevenir o tratar la alergia administrando un antagonista de il-4r.
JP7066691B2 (ja) 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｍｕｃ１６－ｃｄ３抗体および抗ｍｕｃ１６薬物複合体
EA201990781A9 (ru) 2016-09-23 2019-11-27 Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
SG10201913483XA (en) 2016-11-04 2020-03-30 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain locus
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
MA46842A (fr) 2016-11-17 2019-09-25 Regeneron Pharma Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8
KR20190091290A (ko) 2016-11-29 2019-08-05 리제너론 파아마슈티컬스, 인크. Ｐｒｌｒ 양성 유방암 치료 방법
MA46951A (fr) 2016-11-29 2019-10-09 Regeneron Pharma Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
MY191926A (en) 2016-12-01 2022-07-18 Regeneron Pharma Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
EP3558347A1 (en) 2016-12-22 2019-10-30 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
KR102660715B1 (ko) 2017-02-10 2024-04-26 리제너론 파마슈티칼스 인코포레이티드 면역-pet 이미지화를 위한 방사선 라벨링된 항-lag3 항체
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
IL298034B2 (en) 2017-06-01 2024-05-01 Regeneron Pharma Human antibodies to bet v 1 and methods of use thereof
JP7348844B2 (ja) 2017-06-07 2023-09-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 内部移行酵素のための組成物および方法
JP2020524694A (ja) 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
MX2019015477A (es) 2017-06-28 2020-07-28 Regeneron Pharma Proteinas de union a antigeno del virus del papiloma anti-humano (vph) y metodos de uso de las mismas.
US20190010531A1 (en) 2017-07-06 2019-01-10 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
BR112020004336A2 (pt) 2017-09-13 2020-09-08 Jiangsu Hengrui Medicine Co., Ltd. anticorpo il-6r e fragmento de ligação de antígeno do mesmo e uso médico
US10865236B2 (en) 2017-09-29 2020-12-15 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
AU2018359219A1 (en) 2017-10-30 2020-04-23 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing asthma by administering an IL-4R antagonist
BR112020006976A2 (pt) 2017-11-30 2020-10-13 Regeneron Pharmaceuticals, Inc. anticorpos monoclonais anti-trkb e métodos de uso
JP7430636B2 (ja) 2017-12-05 2024-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用
WO2019118556A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
CN111542540A (zh) 2017-12-18 2020-08-14 瑞泽恩制药公司 结合瘦蛋白受体和/或gp130的双特异性抗原结合分子及其使用方法
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
CN115925882A (zh) 2017-12-22 2023-04-07 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
KR20200115517A (ko) 2018-01-26 2020-10-07 리제너론 파마슈티칼스 인코포레이티드 인플루엔자 헤마글루티닌에 대한 인간 항체
SG11202005235WA (en) 2018-01-31 2020-07-29 Regeneron Pharma System and method for characterizing size and charge variant drug product impurities
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
AU2019227531B2 (en) 2018-02-28 2025-01-30 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
EA202092064A1 (ru) 2018-03-01 2020-12-21 Ридженерон Фармасьютикалз, Инк. Способы изменения состава тела
BR112020015291B1 (pt) 2018-03-19 2023-09-26 Regeneron Pharmaceuticals, Inc Tampão de amostra de eletroforese aquoso, método para identificar contaminantes ou impurezas em uma amostra de fármaco proteico, e, kit
JP7382950B2 (ja) 2018-03-26 2023-11-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ＰｆＲＨ５抗体およびその抗原結合断片
WO2019212965A1 (en) 2018-04-30 2019-11-07 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
AU2019265703A1 (en) 2018-05-09 2020-11-19 Regeneron Pharmaceuticals, Inc. Anti-MSR1 antibodies and methods of use thereof
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
IL305557A (en) 2018-06-14 2023-10-01 Regeneron Pharma Non-human animals capable of engineered dh-dh rearrangement and uses thereof
AU2019288299A1 (en) 2018-06-19 2021-01-14 Regeneron Pharmaceuticals, Inc. Anti-Factor XII/XIIa antibodies and uses thereof
EP3810282A1 (en) 2018-06-21 2021-04-28 Regeneron Pharmaceuticals, Inc. Bispecific anti-psma x anti-cd28 antibodies and uses thereof
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
HUE066474T2 (hu) 2018-07-19 2024-08-28 Regeneron Pharma BCMA-specifitással rendelkezõ kiméra antigénreceptorok és azok alkalmazása
CA3108697A1 (en) 2018-08-10 2020-02-13 Regeneron Pharmaceuticals, Inc. A pharmaceutical composition for safe and effective treatment of knee and/or hip pain
MX2021002165A (es) 2018-08-23 2021-07-16 Regeneron Pharma Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos.
WO2020046793A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
JP7504871B2 (ja) 2018-08-29 2024-06-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 関節リウマチを有する対象を治療するための方法および組成物
AU2019333047A1 (en) 2018-08-30 2020-12-03 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
KR20210082207A (ko) 2018-10-23 2021-07-02 리제너론 파아마슈티컬스, 인크. 항-npr1 항체 및 이의 용도
EP3876989A4 (en) * 2018-11-09 2022-12-07 University of Massachusetts Anti-cfae antibodies and methods of use
AU2019384790A1 (en) 2018-11-21 2021-03-18 Regeneron Pharmaceuticals, Inc. Anti-staphylococcus antibodies and uses thereof
MX2021006971A (es) 2018-12-19 2021-07-15 Regeneron Pharma Anticuerpos anti-muc16 x anti-cd28 biespecificos y usos de estos.
JP2022510964A (ja) 2018-12-19 2022-01-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｃｄ２８ｘ抗ｃｄ２２抗体及びその使用
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
SG11202104103XA (en) 2019-01-16 2021-05-28 Regeneron Pharma Methods for characterizing disulfide bonds
WO2020160465A1 (en) 2019-01-31 2020-08-06 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
JP2022519631A (ja) 2019-02-12 2022-03-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 補体および標的抗原に結合する二重特異性抗体を使用するための組成物および方法
AU2020224136A1 (en) 2019-02-21 2021-09-02 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-MET antibodies and bispecific antigen binding molecules that bind MET
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
AU2020240132A1 (en) 2019-03-21 2021-09-16 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
WO2020198009A1 (en) 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. EGFR x CD28 MULTISPECIFIC ANTIBODIES
WO2020210551A1 (en) 2019-04-10 2020-10-15 Regeneron Pharmaceuticals, Inc. Human antibodies that bind ret and methods of use thereof
WO2020219960A1 (en) 2019-04-24 2020-10-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
SG11202111255YA (en) 2019-05-01 2021-11-29 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-33 antagonist
WO2020231992A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
KR20230061198A (ko) 2019-06-04 2023-05-08 사노피 바이오테크놀로지 류마티스성 관절염을 갖는 대상체에서 통증을 치료하기 위한 조성물 및 방법
KR20220016880A (ko) 2019-06-05 2022-02-10 리제너론 파마슈티칼스 인코포레이티드 카파 유전자좌에서 발현된 제한적 람다 경쇄 레퍼토리를 갖는 비-인간 동물 및 이의 용도
MX2021015156A (es) 2019-06-11 2022-01-18 Regeneron Pharma Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
AU2020291946A1 (en) * 2019-06-14 2022-01-06 Dana-Farber Cancer Institute, Inc. Antibodies against PD-1 and methods of use thereof
CA3141628A1 (en) * 2019-06-14 2020-12-17 Dana-Farber Cancer Institute, Inc. Antibodies against pd-1 and methods of use thereof
CN114375205A (zh) 2019-06-20 2022-04-19 武田药品工业株式会社 用基于病毒的基因疗法进行治疗的方法
EP3999114A1 (en) 2019-07-16 2022-05-25 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
US20220281994A1 (en) 2019-07-24 2022-09-08 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors with MAGE-A4 Specificity and Uses Thereof
WO2021055350A1 (en) 2019-09-16 2021-03-25 Regeneron Pharmaceuticals, Inc. Radiolabeled met binding proteins for immuno-pet imaging
US20220323937A1 (en) 2019-09-24 2022-10-13 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
CN114761428A (zh) 2019-10-28 2022-07-15 瑞泽恩制药公司 抗血凝素抗体及其使用方法
KR20220104797A (ko) 2019-11-25 2022-07-26 리제너론 파마슈티칼스 인코포레이티드 비수성 에멀전을 이용한 지속 방출 제형
KR20220110510A (ko) 2019-12-06 2022-08-08 리제너론 파아마슈티컬스, 인크. 이중특이적 항-BCMA x 항-CD3 항체를 이용한 다발성 골수종의 치료 방법
KR20220110553A (ko) 2019-12-06 2022-08-08 사노피 바이오테크놀로지 Il-33 길항제를 투여하여 copd를 치료하는 방법
JP2023508360A (ja) 2019-12-23 2023-03-02 サノフィ・バイオテクノロジー Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法
CA3165060C (en) 2020-01-21 2023-06-20 Yiming Zhao Deglycosylation methods for electrophoresis of glycosylated proteins
EP4093767A1 (en) 2020-01-22 2022-11-30 H. Lee Moffitt Cancer Center & Research Institute, Inc. Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor
WO2021163076A1 (en) 2020-02-10 2021-08-19 Regeneron Pharmaceuticals, Inc. ANTl-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
WO2021163170A1 (en) 2020-02-11 2021-08-19 Regeneron Pharmaceuticals, Inc. Anti-acvr1 antibodies and uses thereof
MX2022010599A (es) 2020-02-28 2022-09-09 Regeneron Pharma Moleculas biespecificas de union al antigeno que se unen a her2, y metodos de uso de los mismos.
AU2021232041A1 (en) 2020-03-06 2022-09-08 Regeneron Pharmaceuticals, Inc. Anti-GITR antibodies and uses thereof
PE20221893A1 (es) 2020-04-02 2022-12-13 Regeneron Pharma Anticuerpos contra glicoproteina de espicula anti-sars-cov-2 y fragmentos de union al antigeno
WO2021226249A1 (en) * 2020-05-06 2021-11-11 Sorrento Therapeutics, Inc. Neutralizing antibodies that bind the sars-cov-2 s protein
MX2022014090A (es) 2020-05-12 2023-02-27 Regeneron Pharma Anticuerpos antagonistas anti-glp1r y metodos de uso de los mismos.
WO2021233246A1 (en) * 2020-05-18 2021-11-25 Biosion Inc. Antibodies binding il6r and uses thereof
JP2023527059A (ja) 2020-05-26 2023-06-26 サノフィ・バイオテクノロジー 関節リウマチを治療するためのインターロイキン６受容体に対する抗体を含む組成物およびその使用方法
US20240043504A1 (en) 2020-05-26 2024-02-08 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
CA3180041A1 (en) 2020-05-29 2021-12-02 Sanofi Biotechnology Compositions and methods for treating non-inflammatory pain in subjects with rheumatoid arthritis
WO2021257695A2 (en) * 2020-06-16 2021-12-23 Hifibio (Hk) Limited Methods and compositions related to neutralizing antibodies against human coronavirus
US20230416343A1 (en) * 2020-08-07 2023-12-28 Sorrento Therapeutics, Inc. Neutralizing Antibodies that Bind the SARS-COV-2 S Protein
EP4200017A1 (en) 2020-08-20 2023-06-28 Regeneron Pharmaceuticals, Inc. Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists
EP4204449A1 (en) 2020-08-26 2023-07-05 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
WO2022047108A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
EP4214234A1 (en) 2020-09-18 2023-07-26 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof
WO2022076289A1 (en) 2020-10-05 2022-04-14 Sanofi Biotechnology Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
CN116406379A (zh) 2020-10-22 2023-07-07 瑞泽恩制药公司 抗fgfr2抗体和其使用方法
MX2023006077A (es) 2020-11-25 2023-06-06 Regeneron Pharma Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
EP4262757A1 (en) 2020-12-17 2023-10-25 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
US20220195058A1 (en) 2020-12-18 2022-06-23 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to npr1 agonists
WO2022140219A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
IL305156A (en) 2021-03-03 2023-10-01 Regeneron Pharma Systems and methods for quantifying and modifying protein viscosity
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
CA3211302A1 (en) 2021-03-26 2022-09-29 Ross Kenyon Methods and systems for developing mixing protocols
BR112023021256A2 (pt) 2021-04-20 2023-12-12 Regeneron Pharma Anticorpos humanos para artemina e métodos de uso dos mesmos
EP4334353A1 (en) 2021-05-04 2024-03-13 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
AU2022271212A1 (en) 2021-05-04 2023-11-30 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
KR20240016991A (ko) * 2021-06-01 2024-02-06 르 라보레또레 쎄르비에르 항-nkg2a 항체 및 조성물
BR112023024984A2 (pt) 2021-06-01 2024-02-20 Regeneron Pharma Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
MX2024000321A (es) 2021-07-05 2024-01-25 Regeneron Pharma Utilizacion de anticuerpos para formar las respuestas de los anticuerpos a un antigeno.
TW202321292A (zh) 2021-07-14 2023-06-01 美商再生元醫藥公司 抗sars-cov-2-棘醣蛋白抗體及抗原結合片段
KR20240037321A (ko) 2021-07-26 2024-03-21 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 만성 자발성 심마진의 치료 방법
AR127006A1 (es) 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
CA3232463A1 (en) 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
US20230110811A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. pH METER CALIBRATION AND CORRECTION
CA3230984A1 (en) 2021-10-07 2023-04-13 Ross BROWNE Systems and methods of ph modeling and control
MX2024004762A (es) 2021-10-20 2024-05-08 Sanofi Biotechnology Metodos para el tratamiento del prurigo nodular mediante la administracion de un antagonista de il-4r.
IL312308A (en) 2021-10-22 2024-06-01 Regeneron Pharma Antibodies that bind to the A2 domain of factor XI and their uses
TW202330104A (zh) 2021-10-26 2023-08-01 美商再生元醫藥公司 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
US20250011408A1 (en) 2021-11-19 2025-01-09 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
AU2022408149A1 (en) 2021-12-06 2024-05-23 Regeneron Pharmaceuticals, Inc. Antagonist anti-npr1 antibodies and methods of use thereof
CN119137473A (zh) 2022-03-18 2024-12-13 里珍纳龙药品有限公司 分析多肽变体的方法及系统
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
WO2023212586A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist
WO2023225098A1 (en) 2022-05-18 2023-11-23 Regeneron Pharmaceuticals, Inc. Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
WO2024015816A1 (en) 2022-07-12 2024-01-18 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
WO2024047021A1 (en) 2022-08-29 2024-03-07 Sanofi Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
WO2024102369A1 (en) 2022-11-07 2024-05-16 Regeneron Pharmaceuticals, Inc. Factor xi catalytic domain-binding antibodies and methods of use thereof
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules
WO2024130048A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2024130165A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
TW202445135A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 液態蛋白質組成物穩定性之建模方法
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
WO2024173248A1 (en) 2023-02-13 2024-08-22 Regeneron Pharmaceuticals, Inc. Treatment of muscle related disorders with anti-human cacng1 antibodies
WO2024173876A1 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
WO2024178213A2 (en) 2023-02-22 2024-08-29 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
WO2024197119A1 (en) 2023-03-22 2024-09-26 Sanofi Biotechnology Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
WO2024229136A1 (en) 2023-05-01 2024-11-07 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
WO2024229105A1 (en) 2023-05-02 2024-11-07 Regeneron Pharmaceuticals, Inc. Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
WO2024259206A1 (en) 2023-06-16 2024-12-19 Regeneron Pharmaceuticals, Inc. Cd40 x cd40 bispecific antigen-binding molecules and uses thereof
WO2025014914A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Bispecific pd-l1x4-1bb antibodies and methods of use thereof
WO2025014533A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Anti-human cacng1 antibody-drug conjugates and uses thereof
US20250043002A1 (en) 2023-07-10 2025-02-06 Regeneron Pharmaceuticals, Inc. BISPECIFIC PD-L1xCD28 ANTIBODIES AND METHODS OF USE THEREOF
WO2025019789A1 (en) 2023-07-19 2025-01-23 Regeneron Pharmaceuticals, Inc. ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
SG42954A1 (en) * 1989-07-20 1997-10-17 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH05227970A (ja) * 1992-02-19 1993-09-07 Chugai Pharmaceut Co Ltd ヒトインターロイキン−６受容体に対する再構成ヒト抗体
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
FR2694767B1 (fr) * 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
WO1994009138A1 (en) 1992-10-20 1994-04-28 Cetus Oncology Corporation Interleukin-6 receptor antagonists
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO1995009873A1 (en) * 1993-10-06 1995-04-13 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
PL186506B1 (pl) 1994-10-07 2004-01-30 Chugai Pharmaceutical Co Ltd Sposób wytwarzania środka farmaceutycznego hamującego wzrost komórek błony maziowej i zastosowanie monoklonalnego przeciwciała
CN1306963C (zh) 1994-10-21 2007-03-28 岸本忠三 用于治疗il－6产生所致疾病的药物组合物
DE69525971T3 (de) 1994-12-29 2013-01-10 Chugai Seiyaku K.K. Verwendung eines pm-1 antikörpers oder eines mh 166 antikörpers zur verstärkung des anti-tumor-effektes von cisplatin oder carboplatin
CA2211578C (en) 1995-02-13 2010-09-21 Chugai Seiyaku Kabushiki Kaisha Muscle protein proteolysis inhibiting agent containing il-6 receptor antibody
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5785965A (en) 1996-05-15 1998-07-28 The Board Of Trustees Of The Leland Stanford Junior Univ. VEGF gene transfer into endothelial cells for vascular prosthesis
AU3276297A (en) 1996-06-27 1998-01-14 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
AU747883B2 (en) 1997-08-15 2002-05-30 Chugai Seiyaku Kabushiki Kaisha Preventives and/or remedies for systemic lupus erythematosus containing anti-IL-6 receptor antibody as the active ingredient
JP4124573B2 (ja) 1998-03-17 2008-07-23 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する炎症性腸疾患の予防又は治療剤
EP1108435B1 (en) 1998-08-24 2007-01-03 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for pancreatitis containing anti-il-6 receptor antibodies as the active ingredient
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
EP1314437B1 (en) 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
AU1091802A (en) 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded agonist antibody
JP4776145B2 (ja) 2000-10-25 2011-09-21 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する乾癬の予防又は治療剤
JP4889187B2 (ja) 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
ES2353496T3 (es) 2002-02-14 2011-03-02 Chugai Seiyaku Kabushiki Kaisha Productos farmacéuticos en solución que contienen anticuerpos.
US20060078531A1 (en) 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060078533A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
CA2496523A1 (en) * 2002-08-30 2004-03-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of the antibody
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
CA2539061A1 (en) 2003-09-22 2005-03-31 Biovation Gmbh & Co. Kg Use of an antagonist of il-6 for treating il-6-mediated diseases
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
DE602005020743D1 (de) 2004-02-11 2010-06-02 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
US20070036788A1 (en) 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
JPWO2006046661A1 (ja) * 2004-10-28 2008-05-22 国立大学法人大阪大学 インターロイキン−６阻害剤
US20060177436A1 (en) 2004-12-16 2006-08-10 Genentech, Inc. Methods for Treating Autoimmune Disorders
EP1850866A4 (en) * 2005-01-27 2009-07-08 Univ California MONOCLONAL THERAPEUTIC ANTIBODIES FOR THE NEUTRALIZATION OF BOTULIN NEUROTOXINES
SI2041177T1 (sl) 2006-06-02 2012-03-30 Regeneron Pharma Visoko afinitetna protitelesa za humani IL receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
RU2319351C1 (ru) * 2006-09-13 2008-03-20 Олег Иванович Квасенков Способ подготовки к хранению яблок свежих специального назначения
EP2081960B1 (en) 2006-10-27 2018-06-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2009109584A1 (en) 2008-03-07 2009-09-11 Ferring International Center S. A. ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX

Also Published As

Publication number Publication date
NZ573557A (en) 2010-08-27
US8183014B2 (en) 2012-05-22
RU2433138C2 (ru) 2011-11-10
IL195393A (en) 2013-07-31
AU2007254831A1 (en) 2007-12-13
IL195393A0 (en) 2011-08-01
CY1113708T1 (el) 2016-06-22
PT2041177E (pt) 2012-03-05
LUC00050I2 (pl) 2018-01-23
US10584173B2 (en) 2020-03-10
KR20090024690A (ko) 2009-03-09
AU2007254831B2 (en) 2012-03-22
MX2008014804A (es) 2009-01-27
LTPA2017038I1 (lt) 2017-12-11
CN101454345A (zh) 2009-06-10
DK2041177T3 (da) 2012-02-27
TNSN08502A1 (en) 2010-04-14
US20130157313A1 (en) 2013-06-20
EP2374818A1 (en) 2011-10-12
HUS1700050I1 (hu) 2017-12-28
US20230094591A1 (en) 2023-03-30
CY2017039I1 (el) 2018-04-04
CN102585002A (zh) 2012-07-18
JP6140777B2 (ja) 2017-05-31
HRP20120175T1 (hr) 2012-03-31
US20210009698A1 (en) 2021-01-14
JP2016026171A (ja) 2016-02-12
CY2017039I2 (el) 2018-04-04
EP2041177A2 (en) 2009-04-01
NO2017060I1 (no) 2017-11-14
ES2377579T3 (es) 2012-03-29
US7582298B2 (en) 2009-09-01
BRPI0712224B1 (pt) 2020-11-17
MY159787A (en) 2017-01-31
CA2652976A1 (en) 2007-12-13
ES2398076T3 (es) 2013-03-13
EP2374818B1 (en) 2012-12-19
CY1112456T1 (el) 2015-12-09
WO2007143168A2 (en) 2007-12-13
US11370843B2 (en) 2022-06-28
US20100316627A1 (en) 2010-12-16
LUC00050I1 (pl) 2017-11-22
NZ587107A (en) 2012-05-25
MY147468A (en) 2012-12-14
WO2007143168A3 (en) 2008-04-24
NO20085309L (no) 2009-03-02
RS52643B (en) 2013-06-28
US9884916B2 (en) 2018-02-06
US8043617B2 (en) 2011-10-25
GT200800272A (es) 2009-08-21
ATE537190T1 (de) 2011-12-15
US20140255995A1 (en) 2014-09-11
PT2374818E (pt) 2013-02-13
ME00519B (me) 2011-10-10
EP2041177B1 (en) 2011-12-14
US20120003697A1 (en) 2012-01-05
RS52176B (en) 2012-08-31
BRPI0712224A2 (pt) 2012-01-17
NL300911I2 (nl) 2018-02-01
NO340778B1 (no) 2017-06-19
DK2374818T3 (da) 2013-01-21
CA2652976C (en) 2015-08-11
US20160229916A1 (en) 2016-08-11
LTC2041177I2 (lt) 2018-09-10
SI2041177T1 (sl) 2012-03-30
SI2374818T1 (sl) 2013-03-29
US20190256606A1 (en) 2019-08-22
JP2009539349A (ja) 2009-11-19
KR101464502B1 (ko) 2014-12-01
PL2374818T3 (pl) 2013-05-31
JP5805703B2 (ja) 2015-11-04
CN101454345B (zh) 2012-08-08
HRP20130228T1 (hr) 2013-04-30
RU2008152443A (ru) 2010-07-20
SV2008003113A (es) 2009-10-27
JP5307708B2 (ja) 2013-10-02
CR10462A (es) 2009-03-20
BRPI0712224B8 (pt) 2021-05-25
US20070280945A1 (en) 2007-12-06
JP2013226143A (ja) 2013-11-07

Similar Documents

Publication Publication Date Title
HUS1700050I1 (hu) Nagy affinitású, humán IL-6 receptorhoz kötõdõ antitestek
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
NZ599497A (en) Humanized antibodies to amyloid beta
NZ623706A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
NO20074867L (no) Antistoffer mot CCR5 og anvendelser derav
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
CO6160305A2 (es) Anticuerpos humanos de alta afinidad para el receptor de il-4 humano
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
RS54113B1 (en) COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
NZ599683A (en) Anti-ilt7 antibody
NZ578943A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
MX2011008843A (es) Anticuerpos humanizados que se unen a cd19 y sus usos.
NZ712765A (en) Antibodies that bind csf1r
NZ585559A (en) Humanized antibodies against tl1a
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
SI2768859T1 (en) Antagonists of il17c for the treatment of inflammatory disorders
NZ781203A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof